Ocular Therapeutix, Inc. (FRA:0OT)
Germany · Delayed Price · Currency is EUR | Market Cap | 2.05B +12.2% |
| Revenue (ttm) | 45.56M -8.1% |
| Net Income | -263.86M |
| EPS | -1.24 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 9.25 |
| Previous Close | 9.30 |
| Day's Range | 9.00 - 9.25 |
| 52-Week Range | 5.68 - 13.66 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Ocular Therapeutix
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of ... [Read more]
Financial Performance
In 2025, Ocular Therapeutix's revenue was $51.95 million, a decrease of -18.47% compared to the previous year's $63.72 million. Losses were -$265.94 million, 37.4% more than in 2024.
Financial numbers in USD Financial StatementsNews
Clear Street sees less competition for Ocular after EyePoint miss
Clear Street reiterates a Buy rating on Ocular Therapeutix (OCUL) (OCLX) after its competitor EyePoint (EYPT) reported the LUGANO study did not meet its primary endpoint. The trial miss potentially…
Ocular Therapeutix rises 10.4%
Ocular Therapeutix (OCUL) is up 10.4%, or $1.04 to $11.08.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experie...
Ocular Therapeutix reports Q2 EPS (35c), consensus (39c)
Reports Q2 revenue $13.48M, consensus $13.2M. “We continue to execute with discipline, precision, and urgency to redefine the retina experience and make AXPAXLI available to patients as early as possi...
Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights
Ocular's AXPAXLI TM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026
Ocular Therapeutix Earnings release: Q2 2026
Ocular Therapeutix released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
Ocular Therapeutix Quarterly report: Q2 2026
Ocular Therapeutix has published its Q2 2026 quarterly earnings report on August 3, 2026.
Ocular Therapeutix Slides: Study Result presentation
Ocular Therapeutix has posted slides in relation to its latest quarterly earnings report, which was published on August 2, 2026.
Ocular Therapeutix Transcript: H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
Alignment with the FDA enables a Q4 NDA submission for AXPAXLI in wet AMD, leveraging strong single-trial data and the 505(b)(2) pathway. The product shows superior durability, robust safety, and is expected to see broad adoption, with commercial and financial readiness in place.
Ocular Therapeutix Slides: American Society of Retina Specialists presentation
Ocular Therapeutix has posted slides in relation to its latest quarterly earnings report, which was published on July 16, 2026.
Ocular Therapeutix Slides: Study result presentation
Ocular Therapeutix has posted slides in relation to its latest quarterly earnings report, which was published on July 16, 2026.
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
BEDFORD, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announ...
Ocular Therapeutix price target raised to $25 from $21 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Ocular Therapeutix (OCUL) to $25 from $21 and keeps a Buy rating on the shares after the company discussed the outcome of…
Ocular Therapeutix price target raised to $30 from $24 at Baird
Baird raised the firm’s price target on Ocular Therapeutix (OCUL) to $30 from $24 and keeps an Outperform rating on the shares. The firm updated its model following its investor…
Ocular Therapeutix Transcript: Investor Day 2026
Formal FDA alignment enables NDA submission for AXPAXLI based on SOL1, which showed superior durability and safety versus aflibercept in wet AMD. Commercial launch is targeted for 2027, with strong physician and payer support for rapid adoption and premium pricing.
Ocular Therapeutix Press release: FY 2026
Ocular Therapeutix issued a press release on June 17, 2026, disclosing material business information to investors.
Ocular Therapeutix Slides: FY 2026
Ocular Therapeutix has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 17, 2026.
Ocular Therapeutix trading resumes
09:15 EDT Ocular Therapeutix (OCUL) trading resumes
Ocular Therapeutix Investor Day to highlight FDA alignment on Axpaxli NDA
Ocular Therapeutix (OCUL) said it will host an Investor Day today to showcase its FDA-aligned plans to submit its NDA for AXPAXLI, also known as OTX-TKI, in wet AMD in…
Ocular Therapeutix to resume trading at 9:15 am ET
Ocular Therapeutix (OCUL), which announced plans to showcase its FDA-aligned plans to submit its NDA for AXPAXLI, is set to resume trading at 9:15am ET, with quotation scheduled to resume…
Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026
Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data
Ocular Therapeutix trading halted, news pending
08:40 EDT Ocular Therapeutix (OCUL) trading halted, news pending
Ocular Therapeutix Transcript: AGM 2026
The meeting, held virtually, covered director elections, executive compensation, and amendments to the stock incentive plan, all of which were approved by strong majorities. No questions were raised by stockholders, and key risks were highlighted in forward-looking statements.
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026
BEDFORD, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announ...
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
In addition to Ocular leadership, event to feature prominent retinal disease experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Lejla Vajzovic, MD, FASRS; and Dr. Darius M.